{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:40:34Z","timestamp":1768707634928,"version":"3.49.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>We reported the outcome of 150 children newly diagnosed with multisystem langerhans cell histiocytosis following a langerhans cell histiocytosis-II-based protocol (arm B). However, the continuation treatment was extended to 56 weeks and etoposide was omitted from the continuation treatment. Risk organ (RO) involvement was defined as: liver (\u22653\u2009cm with or without functional impairment); spleen (\u22652\u2009cm below the costal margin in the midclavicular line); hematopoietic system (hemoglobin &lt;100\u2009g\/L, and\/or white blood cell count &lt;4.0\u00d710<jats:sup>9<\/jats:sup>\/L, and\/or platelets &lt;100\u00d710<jats:sup>9<\/jats:sup>\/L). The lungs are not considered a RO in the current study. For the 59 patients with RO involvement (RO+), the rapid response rate (week 6) was 61.0% and the 3-year overall survival 73.4%\u00b15.9%. Rapid responders had a better 3-year survival rate than poor responders (90.9%\u00b15.0% vs. 45.7%\u00b111.0%, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). Ninety-one patients without RO involvement (RO\u2212) had a relatively low 3-year cumulative reactivation rate (10.7%). No deaths occurred in this subgroup and the 3-year overall survival of RO\u2212 patients was 100%. Poor responders of RO+ patients had an extremely poor prognosis. An effective salvage therapy is essential for this high-risk group. The initial treatment intensity and duration of continuation therapy both impact disease reactivation in RO\u2212 patients.<\/jats:p>","DOI":"10.1097\/mph.0000000000001016","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T23:20:37Z","timestamp":1512170437000},"page":"e9-e12","source":"Crossref","is-referenced-by-count":13,"title":["Treatment Outcome of Children With Multisystem Langerhans Cell Histiocytosis: The Experience of a Single Children\u2019s Hospital in Shanghai, China"],"prefix":"10.1097","volume":"40","author":[{"given":"Yi-Jin","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ci","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20240202","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1067\/mpd.2001.111331","article-title":"A randomized trial of treatment for multisystem Langerhans\u2019 cell histiocytosis","volume":"138","author":"Gadner","year":"2001","journal-title":"J Pediatr"},{"key":"R2-20240202","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","article-title":"Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification","volume":"111","author":"Gadner","year":"2008","journal-title":"Blood"},{"key":"R3-20240202","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"key":"R5-20240202","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0022-3476(75)80576-2","article-title":"Histiocytosis X: an analysis of prognostic factors","volume":"87","author":"Lahey","year":"1975","journal-title":"J Pediatr"},{"key":"R6-20240202","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpeds.2011.12.035","article-title":"Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome","volume":"161","author":"Ronceray","year":"2012","journal-title":"J Pediatr"},{"key":"R7-20240202","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/mpo.2950230203","article-title":"Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group","volume":"23","author":"Gadner","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"R8-20240202","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12185-016-1993-3","article-title":"Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study","volume":"104","author":"Morimoto","year":"2016","journal-title":"Int J Hematol"},{"key":"R9-20240202","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/bjc.2012.191","article-title":"Registration of cancer in girls remains lower than expected in countries with low\/middle incomes and low female education rates","volume":"107","author":"Bhopal","year":"2012","journal-title":"Br J Cancer"},{"key":"R10-20240202","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.12122","article-title":"Improved outcome for children with non-high risk acute lymphoblastic leukaemia using an ALL IC-BFM 2002-based protocol in Shanghai, China","volume":"160","author":"Gao","year":"2013","journal-title":"Br J Haematol"},{"key":"R11-20240202","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pbc.24848","article-title":"Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010","volume":"61","author":"Gao","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20240202","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2015-03-635151","article-title":"Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study","volume":"126","author":"Donadieu","year":"2015","journal-title":"Blood"},{"key":"R13-20240202","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy","volume":"34","author":"H\u00e9ritier","year":"2016","journal-title":"J Clin Oncol"},{"key":"R14-20240202","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/1097-0142(19881215)62:12<2528::AID-CNCR2820621213>3.0.CO;2-#","article-title":"Etoposide in recurrent childhood Langerhans\u2019 cell histiocytosis: an Italian cooperative study","volume":"62","author":"Ceci","year":"1988","journal-title":"Cancer"},{"key":"R15-20240202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mpo.2950170205","article-title":"Etoposide (VP-16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X)","volume":"17","author":"Broadbent","year":"1989","journal-title":"Med Pediatr Oncol"},{"key":"R16-20240202","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/bjh.13208","article-title":"Up-front therapy for LCH: is it time to test an alternative to vinblastine\/prednisone?","volume":"169","author":"Simko","year":"2015","journal-title":"Br J Haematol"},{"key":"R17-20240202","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/bjh.13955","article-title":"Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy","volume":"173","author":"Arico","year":"2016","journal-title":"Br J Haematol"},{"key":"R18-20240202","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/11538540-000000000-00000","article-title":"Multisystem Langerhans cell histiocytosis in children: current treatment and future directions","volume":"13","author":"Minkov","year":"2011","journal-title":"Paediatr Drugs"},{"key":"R19-20240202","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2014-12-569301","article-title":"How I treat Langerhans cell histiocytosis","volume":"126","author":"Allen","year":"2015","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201801000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T16:03:45Z","timestamp":1706889825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201801000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001016","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}